CoChat

Adenosine Kinase Inhibitor GP515 Improves Experimental Colitis in Mice

Siegmund, Britta, Rieder, Florian, Albrich, Stefan, Wolf, Katrin, Bidlingmaier, Christoph, Firestein, Gary S., Boyle, David, Lehr, Hans-Anton, Loher, Florian, Hartmann, Gunther, Endres, Stefan, Eigler, Andreas · 2001 · The Journal of Pharmacology and Experimental Therapeutics
Cited by 128

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Adenosine is a potent anti-inflammatory mediator. Through elevation of endogenous adenosine concentrations the adenosine kinase inhibitor GP515 might serve to down-regulate local inflammatory responses. In the present study we investigated the effect of systemic GP515 in the nonacute model of dextran sulfate sodium (DSS)-induced colitis. The clinical score, colon length, histologic score, colon cytokine production, and spleen weight from mice with DSS-induced colitis (3.5% DSS in drinking water for 11 days) receiving GP515 treatment were determined and compared with untreated control mice. Splenocytes were analyzed for phenotype, interferon-gamma (IFNgamma) production, and CD69 expression. First, GP515 treatment resulted in a significant improvement of clinical score (weight loss, stool consistency, and bleeding) and of histologic score. Second, colon shortening, an indirect parameter for the degree of inflammation, was decreased, consistent with a decreased IFNgamma concentration in the colonic tissue. Third, spleen weight was reduced in GP515-treated DSS mice. And fourth, IFNgamma synthesis and CD69 expression, as a marker for early cell activation, of ex vivo-stimulated splenocytes were suppressed in the GP515-treated DSS mice. These studies show that GP515 is effective in the therapy of DSS-induced colitis. One potential mechanism of action is the suppression of IFNgamma synthesis and CD69 expression. Adenosine kinase inhibition forms a pharmacologic target that should be further investigated for chronic inflammatory bowel disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0022-3565(24)29668-3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 128

Metadata

Authors
Siegmund, B., Rieder, F., Albrich, S., Wolf, K., Bidlingmaier, C., Firestein, G. S., Boyle, D., Lehr, H.-A., Loher, F., Hartmann, G., Endres, S., & Eigler, A.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2001-01
Volume
296
Issue
1
Pages
99-105
ISSN
0022-3565 (ISSN-L)
OpenAlex
W1905926188
Cited by
128
References
1
FWCI
3.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adenosine Kinase Inhibitor GP515 Improves Experimental Colitis in Mice. https://app.cochat.ai/papers/10.1016/s0022-3565(24)29668-3
The paper
Siegmund, B., Rieder, F., Albrich, S., Wolf, K., Bidlingmaier, C., Firestein, G. S., Boyle, D., Lehr, H.-A., Loher, F., Hartmann, G., Endres, S., & Eigler, A. (2001). Adenosine Kinase Inhibitor GP515 Improves Experimental Colitis in Mice. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)29668-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.